Article Text

Download PDFPDF

E-188 How far can we go? – WEB technology for the treatment of sidewall IA. Initial experience in a single institution
  1. B Pabon Guerrero,
  2. J Gutierrez Banos,
  3. M Patino Hoyos,
  4. V Torres,
  5. L Moreira Ponce,
  6. O Vargas,
  7. J Mejia
  1. Neurointevencionismo, AngiTeam, Medellin, Colombia


Introduction Few years after introduction, Flow disruption technology using WEB device has been used safely for the treatment of wide-neck bifurcation aneurysms, but the use of this endosaccular approach to treat side-wall lesions in terms of feasibility, safety, stability and aneurysm occlusion rate after this treatment is unknown.

Materials and Methods Patients were carefully selected IRB approved. Clinical, anatomical, angiographical and technical considerations were analyzed. Procedure related complications, procedural time, antiplatelet therapy requirements. Web Occlusion Scale (WOS) was used for the Follow-up.

Results From August 2017 and March 2020 a total of six wide-necked, sidewall, IA were selected for WEB treatment. Aneurysm mean size 5.3 mm in width and 5.8 in height. Aneurysm Location: ICA 3 cases (two Carotid-ophtalmic segment, one AChoA segment), Superior Cerebellar Artery SCA in two patients (33%), and one impressive case in posterior circulation associated with a basilar fenestration next to VBJ. Four cases were unruptured (66%), and two cases with history of SAH. DAPT used pre operatively in all cases but none patient remain under antiplatelets after procedure. Technical success of 100%. Mean procedure time: 24 min. None related procedure complications recorded. Immediately angiographic occlusion was evidenced in 3 cases (two SCA and one ICA). Radiological Follow up (ranging 1-26 months) available in 4/6 showed a WOS adequate occlusion in all cases.

Conclusion In our early experience using WEB device to treat different conditions than bifurcation IA´s, the results showed that endossacular approach was feasible in highly selected patients, safety profile in agreement with previous bifurcation experiences and very effective to treat challenge cases with a high probability of recurrence or therapeutic failure. Larger series and controlled studies are required to expand its indications in a near future.

Disclosures B. Pabon Guerrero: None. J. Gutierrez Banos: None. M. Patino Hoyos: None. V. Torres: None. L. Moreira Ponce: None. O. Vargas: None. J. Mejia: None.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.